Survival after progression in patients with follicular lymphoma: Analysis of prognostic factors

Annals of Oncology

Volumn 13, Issue 4, 2002, Pages 523-530

  Montoto, S ^a   Lopez Guillermo A ^a   Ferrer, A ^a   Camos M ^a   Alvarez Larran A ^a   Bosch, F ^a   Blade J ^a   Cervantes, F ^a   Esteve, J ^a   Cobo, F ^a   Colomer, D ^a   Campo, E ^a   Montserrat, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Follicular lymphoma; Outcome; Progression

Indexed keywords

ALKYLATING AGENT; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HIGH RISK PATIENT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STEM CELL TRANSPLANTATION;

AGE FACTORS; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036242143     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf119     Document Type: Article

References (48)

1. Follicular lymphoma: Prognostic factors for response and survival
2. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model
3. The management of follicular lymphoma
4. Low-grade lymphoma: Clinical and prognostic studies in a series of 143 patients from a single institution
5. Low-grade non-Hodgkin's lymphoma - Development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND)
6. Fludarabinemitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma
7. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
8. Zevalin ™ (IDEC-Y2B8) radio-immunotherapy of Rituximab refractory follicular non-Hodgkin's lymphoma (NHL): Interim results
9. Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology
10. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
11. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma
12. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
13. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
14. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
15. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
16. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
17. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
18. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
19. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
20. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-Airlie House, Virginia, November, 1997
21. A predictive model for aggressive non-Hodgkin's lymphoma: The International NHL Prognostic Factors Project
22. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
23. Survival after relapse of low-grade non-Hodgkin's lymphoma: Implications for marrow transplantation
24. Nonparametric estimation from incomplete observations
25. 2/E in the log-rank test for survival data or tumor incidence data
26. Regression models and life tables
27. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
28. Nodular malignant lymphomas: Factors affecting complete response rate and survival
29. Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients
30. Prognostic value of serum β-2 microglobulin in low-grade lymphoma
31. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma
32. Identification of prognostic groups in follicular lymphoma
33. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases
34. Prognostic factors in follicular lymphomas
35. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma
36. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
37. Comparison of M-2 protocol with COP in patients with nodular lymphoma
38. Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen
39. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment
40. Stage I-II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy
41. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University
42. Outcome of advanced stage low grade follicular lymphomas in a population-based retrospective cohort
43. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
44. Therapy of relapsed or refractory low-grade follicular lymphomas: Factors associated with complete remission, survival and time to treatment failure
45. Prolonged survival in follicular non Hodgkin's lymphoma is predicted by achievement of complete remission with initial treatment: Results of a long term study with multivariate analysis of prognostic factors
46. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
47. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance abnormalities
48. The clinical significance of molecular response in indolent follicular lymphomas